We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Optibiotix Health Plc | LSE:OPTI | London | Ordinary Share | GB00BP0RTP38 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 18.25 | 17.50 | 19.00 | 18.25 | 18.25 | 18.25 | 44,934 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Noncomml Resh Organizations | 457k | 2.59M | 0.0284 | 6.43 | 16.64M |
Date | Subject | Author | Discuss |
---|---|---|---|
07/6/2018 12:06 | Gut mania’ has put consumers around the world ahead of the science. Despite the ever-increasing number of probiotic supplements, foods, and beverages, consumers are confused about what they are, how they work, and why they should take them. The science of probiotics demands precision, accountability, and efficacy. We combine human clinical research, proprietary technology, and innovations in biofermentation, formulation, stabilization, and testing, to set a new standard for bacteria. Mumbo jumbo “The science of probiotics demands precision, accountability, and efficacy” Ok, lets see how they get there and the results of their claims. Efficacy? Show the proof that we can understand and see. Are there humans walking around that have improved health from these products? If there are, then let us know who and where they are. | rayrac | |
07/6/2018 11:47 | I reckon as share holders we should get a decent discount....bring it up at the AGM? | glennrcharles | |
07/6/2018 11:40 | I’m sorry Nobby, but if it has an effect on the body as they claim, then I’d want to see trials that validated the product...on humans. The only trial I’ve seen, claims no more benefit than Benecol for cholesterol. And far more expensive! | rayrac | |
07/6/2018 11:33 | >> rayrac You are dong yourself a disservice by posting such nonsense. There is no need to do Pharma like clinical trials for such a product. If they did, the cost of the trials would be exorbitant and the product would have to be priced very high. It is just a ridiculous thing to suggest..... Nobby | nobbygnome | |
07/6/2018 11:33 | That’s all youve got to say ...mate? Like the product mate, you’re useless. ;) | rayrac | |
07/6/2018 11:26 | I see Mr UKOG's here Hows things looking over there Mate? | judijudi | |
07/6/2018 11:19 | Our Daily Synbiotic was developed for systemic benefits beyond digestive health—the first in a pipeline of scientifically-valid Phase 1/2/3 trials on the human body? Of course not, its notaffective enough to bother real scientists in testing it! And what will this jar of capsules cost here in this country? £50 month? A so called health product like the rest of health care products...useless. | rayrac | |
07/6/2018 10:16 | Only available in the US (International shipping to come). But, they need to make this available to directly purchase in the UK and EU....message sent to them! | undertaker | |
07/6/2018 10:16 | Does look great, but of course and yet again, no impact on share price. I do think Opti need to up their PR game. | mouse20 | |
07/6/2018 10:06 | The SEED product looks amazing.. the collective brain power used to create the products are incredibly impressive. I was a bit concerned people may be put off by having to take 3 capsules per day, but thankfully you can take them all together in the morning! | trotterstrading | |
07/6/2018 10:04 | Yes extra with shipping though | trotterstrading | |
07/6/2018 10:02 | Go on to the website and see if you can subscribe? | toadhall1 | |
07/6/2018 09:28 | will that Seed product be available to buy in the UK? I want some for myself! | undertaker | |
07/6/2018 09:00 | We will soon be into H2 when Galenicum Special Ingredients will be launching Cardiocare. | parob | |
07/6/2018 08:54 | Possibly AIM working. OPTI seems to have a price. | m4rtinu | |
07/6/2018 08:41 | I was thinking I was doing well this morning with nothing in the red too :) | woodaldo | |
07/6/2018 08:39 | Thanks, thought my iPad gone iffy.... | joyjoy13 | |
07/6/2018 08:27 | No point ramping today, LSE has crashed. x | incanus | |
07/6/2018 08:26 | For those of you wondering why no price move, there is a glitch with the market, delayed opening. Must be using TSB's IT team. | woodaldo | |
07/6/2018 08:22 | I liked the fact they have an article in VOGUE simply because it makes a change from the usual scientific research magazines, New Scientist etc etc. It’s getting out there in the general public, which is key in my humble opinion! Just my thoughts and observations.... No ramping required! | joyjoy13 | |
07/6/2018 08:15 | LP-LDL is key to the Seed symbiotic. Without it it would be like putting unleaded in your diesel. | elrico | |
07/6/2018 08:12 | Note that in the Coveteur article LPLDL gets a specific mention.That would not happen unless it is a 'must have' in the Seed mix. | aspex | |
07/6/2018 07:49 | This should be very big news for OPTI. The criticism of the nay sayers is that there are no revenues from all the progress made so far in deals. Here we have tangible evidence that revenues are beginning to flow! But no doubt the price will be a damp squib today. Sometimes I despair of AIM.... Nobby | nobbygnome | |
07/6/2018 07:39 | Good article Parob. However... 'Shelfability'! wtf. | dire cons |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions